Page 5 - Nicolas Poirier News Today : Breaking News, Live Updates & Top Stories | Vimarsana

OSE Immunotherapeutics Announces H1 2023 Results and Provides Corporate Update

OSE Immunotherapeutics Announces H1 2023 Results and Provides Corporate Update
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesNoord hollandFlorence portejoieNicolas poirierAnne laure autret cornetEric leireSciences advances trilleaudUniversity hospital of nantesSpanish drug agencyAmerican society of hematologyVeloxis pharmaceuticals incInternational phaseSciences advancesNantes university hospitalEuropean medicines agency to lusvertikimabBoehringer ingelheim

OSE Immunotherapeutics SA: OSE Immunotherapeutics Announces H1 2023 Results and Provides Corporate Update

OSE Immunotherapeutics SA: OSE Immunotherapeutics Announces H1 2023 Results and Provides Corporate Update
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesNoord hollandEric leireAnne laure autret cornetNicolas poirierFlorence portejoieSciences advances trilleaudUniversity hospital of nantesSpanish drug agencyAmerican society of hematologyInternational phaseVeloxis pharmaceuticals incSciences advancesNantes university hospitalEuropean medicines agency to lusvertikimabBoehringer ingelheim

WATCH: Tedopi, positive results for a lung cancer vaccine

WATCH: Tedopi, positive results for a lung cancer vaccine
iol.co.za - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from iol.co.za Daily Mail and Mail on Sunday newspapers.

United statesBenjamin besseInstitut gustave roussyNicolas poirierClinical researchProfessor benjamin besse

Tedopi: positive results for a lung cancer vaccine

One year after the start of treatment, 44.1% of these patients were still alive in the group receiving the vaccine, compared with only 27.5% in the chemotherapy group, according to the results of a phase 3 clinical trial

United statesBenjamin besseNicolas poirierInstitut gustave roussyClinical researchProfessor benjamin besse

New lung cancer vaccine created in France could be a game changer

A French biotechnology company has produced a vaccine that was effective in decreasing deaths in people with some lung cancers by 41%.

United statesBenjamin besseNicolas poirierImmunotherapeutic tedopiGustave roussy instituteProfessor benjamin bessePhase threePhase oneChief executive officer